BofA takes the opposite side from Bernstein on $CRWV
BofA reiterates BUY with a $140 PT vs Bernstein's $74. That's almost a $70 gap.
That is the sharpest contrast with Bernstein, who modeled losses every year through 2029 and never reached profit.
Both banks agree that Q2
Bernstein is actually the only one that's very bearish on $CRWV loll
The firm rates it as UNDERPERFORM. Its PT is slightly raised from $67 to $74, which still implies a 31% downside from the current price and is also the lowest PT as well.
Meanwhile,
- BofA Securities:
Bernstein is actually the only one that's very bearish on $CRWV loll
The firm rates it as UNDERPERFORM. Its PT is slightly raised from $67 to $74, which still implies a 31% downside from the current price and is also the lowest PT as well.
Meanwhile,
- BofA Securities:
BERNSTEIN: The more $CRWV grows, the more it has to borrow, and the financing drag keeps net income negative for as far out as they forecast.
Bernstein rates CoreWeave Underperform for the long term for 2 reasons:
First, they expect CRWV's long-term revenue to land well below
BERNSTEIN: The more $CRWV grows, the more it has to borrow, and the financing drag keeps net income negative for as far out as they forecast.
Bernstein rates CoreWeave Underperform for the long term for 2 reasons:
First, they expect CRWV's long-term revenue to land well below
Do $CRWV investors even read the numbers of the company they own?
Yes, the company did ~2x its revenues, but also ~4x its losses⚠️Do you know what this means? Those revenues were BOUGHT with the cash inflow from debt issuances, not generated by healthy business growth
Michael Burry was proven wrong, at least during the $NBIS earnings session.
$NBIS surged 35% on earnings day, showing that the compute shortage is turning into something much bigger for Nebius - pricing power, higher margins, and better financing terms, as per @StockSavvyShay.
Nebius earnings tomorrow will decide whether Michael Burry was right in hindsight.
Goldman Sachs reiterates its BUY rating on $NBIS and maintains its $286 price target, the highest TP among those we've tracked.
Worth noting that Goldman Sachs reported a 7.2% stake in $NBIS.
•